查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1178050

抗凝劑的全球市場:藥物類別(XA因子抑制劑(NOAC/DOAC)，肝素，直接凝血酶抑制劑，維他命K拮抗劑)-產業分析，市場規模，佔有率，成長，趨勢，預測(2022年～2031年)

Anticoagulants Market (Drug Class: Factor XA Inhibitors [NOAC/DOAC], Heparins, and Direct Thrombin inhibitors, and Vitamin K Antagonists) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 175 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球抗凝劑市場相關調查分析，提供市場概要，市場分析，競爭情形等系統性資訊。

目錄

第1章 序文

第2章 前提與調查手法

第3章 摘要整理:全球抗凝固藥市場

第4章 市場概要

  • 簡介
    • 市場區隔定義
    • 產業的演進/發展
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球抗凝固藥市場分析與預測(2017年～2031年)
    • 市場收益預測(10億美元)

第5章 主要洞察

  • 主要的產業活動(合併和收購，產品的銷售，夥伴關係等)
  • 新的口服抗凝固藥(NOAC)概要
  • 主要疾病的流行病學
  • COVID-19疫情對產業的影響

第6章 全球抗凝固藥市場分析與預測:各類藥物

  • 簡介和定義
  • 主要調查結果/開發
  • 市場金額預測(2017年～2031年):各類藥物
    • XA因子抑制劑(NOAC/DOAC)
    • 肝素
    • 直接凝血酶抑制劑
    • 維他命K拮抗劑
  • 市場魅力分析:各類藥物

第7章 全球抗凝固藥市場分析與預測:各給藥途徑

  • 簡介和定義
  • 主要調查結果/開發
  • 市場金額預測(2017年～2031年):各給藥途徑
    • 口服
    • 注射
  • 市場魅力分析:各給藥途徑

第8章 全球抗凝固藥市場分析與預測:各適應症

  • 簡介和定義
  • 主要調查結果/開發
  • 市場金額預測(2017年～2031年):各適應症
    • 深部靜脈血栓症
    • 肺動脈栓塞
    • 心房顫動和心臟病發作
    • 缺血性中風
    • 其他
  • 市場魅力分析:各適應症

第9章 全球抗凝固藥市場分析與預測:各流通管道

  • 簡介和定義
  • 主要調查結果/開發
  • 市場金額預測(2017年～2031年):各流通管道
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場魅力分析:各流通管道

第10章 全球抗凝固藥市場分析與預測:各地區

  • 主要調查結果
  • 市場金額預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力分析:各地區

第11章 北美的抗凝固藥市場分析與預測

第12章 歐洲的抗凝固藥市場分析與預測

第13章 亞太地區的抗凝固藥市場分析與預測

第14章 南美的抗凝固藥市場分析與預測

第15章 中東及非洲的抗凝固藥市場分析與預測

第16章 競爭情形

  • 市場參與企業:競爭矩陣(各等級及各企業規模)
  • 市場佔有率/排行榜分析(2021年):各企業
  • 企業簡介
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol Myers Squibb
    • Daiichi Sankyo Company
    • Sanofi
    • Johnson &Johnson
    • Pfizer, Inc.
Product Code: TMRGL60924

TMR's report on the global anticoagulants market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global anticoagulants market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anticoagulants market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anticoagulants market.

The report delves into the competitive landscape of the global anticoagulants market. Key players operating in the global anticoagulants market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global anticoagulants market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anticoagulants Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Anticoagulants Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Key industry events (mergers & acquisitions, product launches, partnerships, etc.)
  • 5.2. Overview on the Novel Oral Anticoagulants (NOACs)
  • 5.3. Epidemiology of the Key Diseases
  • 5.4. Covid-19 Pandemic Impact on the Industry

6. Global Anticoagulants Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Factor XA Inhibitors (NOAC/DOAC)
    • 6.3.2. Heparins
    • 6.3.3. Direct Thrombin Inhibitors
    • 6.3.4. Vitamin K Antagonists
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Anticoagulants Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Injectable
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Anticoagulants Market Analysis and Forecast, by Indication

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Indication, 2017-2031
    • 8.3.1. Deep Vein Thrombosis
    • 8.3.2. Pulmonary Embolism
    • 8.3.3. Atrial Fibrillation & Heart Attack
    • 8.3.4. Ischemic Stroke
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis, by Indication

9. Global Anticoagulants Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Anticoagulants Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Anticoagulants Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Factor XA Inhibitors (NOAC/DOAC)
    • 11.2.2. Heparins
    • 11.2.3. Direct Thrombin Inhibitors
    • 11.2.4. Vitamin K Antagonists
  • 11.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.3.1. Oral
    • 11.3.2. Injectable
  • 11.4. Market Value Forecast, by Indication, 2017-2031
    • 11.4.1. Deep Vein Thrombosis
    • 11.4.2. Pulmonary Embolism
    • 11.4.3. Atrial Fibrillation & Heart Attack
    • 11.4.4. Ischemic Stroke
    • 11.4.5. Others
  • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Route of Administration
    • 11.7.3. By Indication
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country

12. Europe Anticoagulants Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Factor XA Inhibitors (NOAC/DOAC)
    • 12.2.2. Heparins
    • 12.2.3. Direct Thrombin Inhibitors
    • 12.2.4. Vitamin K Antagonists
  • 12.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.3.1. Oral
    • 12.3.2. Injectable
  • 12.4. Market Value Forecast, by Indication, 2017-2031
    • 12.4.1. Deep Vein Thrombosis
    • 12.4.2. Pulmonary Embolism
    • 12.4.3. Atrial Fibrillation & Heart Attack
    • 12.4.4. Ischemic Stroke
    • 12.4.5. Others
  • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Class
    • 12.7.2. By Route of Administration
    • 12.7.3. By Indication
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Anticoagulants Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Factor XA Inhibitors (NOAC/DOAC)
    • 13.2.2. Heparins
    • 13.2.3. Direct Thrombin Inhibitors
    • 13.2.4. Vitamin K Antagonists
  • 13.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.3.1. Oral
    • 13.3.2. Injectable
  • 13.4. Market Value Forecast, by Indication, 2017-2031
    • 13.4.1. Deep Vein Thrombosis
    • 13.4.2. Pulmonary Embolism
    • 13.4.3. Atrial Fibrillation & Heart Attack
    • 13.4.4. Ischemic Stroke
    • 13.4.5. Others
  • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Class
    • 13.7.2. By Route of Administration
    • 13.7.3. By Indication
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America Anticoagulants Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Factor XA Inhibitors (NOAC/DOAC)
    • 14.2.2. Heparins
    • 14.2.3. Direct Thrombin Inhibitors
    • 14.2.4. Vitamin K Antagonists
  • 14.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.3.1. Oral
    • 14.3.2. Injectable
  • 14.4. Market Value Forecast, by Indication, 2017-2031
    • 14.4.1. Deep Vein Thrombosis
    • 14.4.2. Pulmonary Embolism
    • 14.4.3. Atrial Fibrillation & Heart Attack
    • 14.4.4. Ischemic Stroke
    • 14.4.5. Others
  • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Class
    • 14.7.2. By Route of Administration
    • 14.7.3. By Indication
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Anticoagulants Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Class, 2017-2031
    • 15.2.1. Factor XA Inhibitors (NOAC/DOAC)
    • 15.2.2. Heparins
    • 15.2.3. Direct Thrombin Inhibitors
    • 15.2.4. Vitamin K Antagonists
  • 15.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 15.3.1. Oral
    • 15.3.2. Injectable
  • 15.4. Market Value Forecast, by Indication, 2017-2031
    • 15.4.1. Deep Vein Thrombosis
    • 15.4.2. Pulmonary Embolism
    • 15.4.3. Atrial Fibrillation & Heart Attack
    • 15.4.4. Ischemic Stroke
    • 15.4.5. Others
  • 15.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Retail Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Drug Class
    • 15.7.2. By Route of Administration
    • 15.7.3. By Indication
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Market Share/Ranking Analysis, by Company, 2021
  • 16.3. Company Profiles
    • 16.3.1. Bayer AG
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. SWOT Analysis
      • 16.3.1.4. Strategic Overview
    • 16.3.2. Boehringer Ingelheim International GmbH
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. SWOT Analysis
      • 16.3.2.4. Strategic Overview
    • 16.3.3. Bristol Myers Squibb
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. SWOT Analysis
      • 16.3.3.4. Strategic Overview
    • 16.3.4. Daiichi Sankyo Company
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. SWOT Analysis
      • 16.3.4.4. Strategic Overview
    • 16.3.5. Sanofi
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. SWOT Analysis
      • 16.3.5.4. Strategic Overview
    • 16.3.6. Johnson & Johnson
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. SWOT Analysis
      • 16.3.6.4. Strategic Overview
    • 16.3.7. Pfizer, Inc.
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. SWOT Analysis
      • 16.3.7.4. Strategic Overview

List of Tables

  • Table 01: Global Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
  • Table 02: Global Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
  • Table 03: Global Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
  • Table 04: Global Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 05: Global Anticoagulants Market Size (US$ Bn) and Volume (Units) Forecast, by Region, 2017-2031
  • Table 06: North America Anticoagulants Market Value (US$ Bn) Forecast, by Country, 2017-2031
  • Table 07: North America Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
  • Table 09: North America Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
  • Table 10: North America Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 11: Europe Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
  • Table 13: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
  • Table 14: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
  • Table 15: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Asia Pacific Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
  • Table 18: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
  • Table 19: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
  • Table 20: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Latin America Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
  • Table 23: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
  • Table 24: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
  • Table 25: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 26: Middle East & Africa Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
  • Table 28: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
  • Table 29: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
  • Table 30: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Anticoagulants Market Snapshot
  • Figure 02: Global Anticoagulants Market Segments With Leading Market Share (%), 2021
  • Figure 03: Key Industry Developments (Anticoagulants Market)
  • Figure 04: Global Anticoagulants Market Value (US$ Bn) Forecast, 2017-2027
  • Figure 05: Global Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021
  • Figure 06: Global Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021
  • Figure 07: Global Anticoagulants Market Value Share Analysis (%), by Indication, 2021
  • Figure 08: Global Anticoagulants Market Value Share Analysis (%), by Distribution Channel, 2021
  • Figure 09: Global Anticoagulants Market Value Share Analysis (%), by Region, 2021
  • Figure 10: Global Anticoagulants Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 11: Global Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 12: Global Anticoagulants Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 13: Global Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 14: Global Anticoagulants Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 15: Global Anticoagulants Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 16: Global Anticoagulants Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 17: Global Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 18: Global Anticoagulants Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 19: Global Anticoagulants Market Attractiveness Analysis, by Region, 2017-2031
  • Figure 20: North America Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 21: North America Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031
  • Figure 22: North America Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 23: North America Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031
  • Figure 24: North America Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 25: North America Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031
  • Figure 26: North America Anticoagulants Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 27: North America Anticoagulants Market Value Share Analysis (%), by Distribution Channel, 2021 and 2031
  • Figure 28: North America Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 29: North America Anticoagulants Market Value Share Analysis (%), by Country, 2021 and 2031
  • Figure 30: North America Anticoagulants Market Attractiveness Analysis, by Country, 2021 and 2031
  • Figure 31: Europe Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 32: Europe Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031
  • Figure 33: Europe Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 34: Europe Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031
  • Figure 35: Europe Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 36: Europe Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031
  • Figure 37: Europe Anticoagulants Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 38: Europe Anticoagulants Market Value Share Analysis (%), by Distribution Channel, 2021 and 2031
  • Figure 39: Europe Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 40: Europe Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031
  • Figure 41: Europe Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 42: Asia Pacific Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 43: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031
  • Figure 44: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 45: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031
  • Figure 46: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 47: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031
  • Figure 48: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 49: Asia Pacific Anticoagulants Value Share Analysis (%), by Distribution Channel, 2021 and 2031
  • Figure 50: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 51: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031
  • Figure 52: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 53: Latin America Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 54: Latin America Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031
  • Figure 55: Latin America Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 56: Latin America Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031
  • Figure 57: Latin America Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 58: Latin America Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031
  • Figure 59: Latin America Anticoagulants Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 60: Latin America Anticoagulants Value Share Analysis (%), by Distribution Channel, 2021 and 2031
  • Figure 61: Latin America Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 62: Latin America Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031
  • Figure 63: Latin America Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 64: Middle East & Africa Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 65: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031
  • Figure 66: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 67: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031
  • Figure 68: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 69: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031
  • Figure 70: Middle East & Africa Anticoagulants Value Share Analysis (%), by Distribution Channel, 2021 and 2031
  • Figure 71: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 72: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031
  • Figure 73: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022-2031